Skip to main content

Advertisement

SpringerLink
Log in

Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases

  • Case Report
  • Published:
Osteoporosis International Aims and scope Submit manuscript

Abstract

We report on the clinical and biochemical outcomes in two adult patients with active polyostotic fibrous dysplasia (FD) treated with the RANK-L inhibitor, denosumab, following unsatisfactory responses to prior long-term bisphosphonate therapy. A 44-year-old female (case 1) who had received a cumulative dose of 20 mg zoledronic acid over 2.5 years and a 48-year-old male (case 2) who had received a cumulative dose of 45 mg zoledronic acid over 8 years both experienced minimal reductions in pain scores and markers of bone turnover. Following initiation of denosumab 60 mg sc, changes in bone pain, bone turnover [assessed by serum amino-terminal propeptide of type I collagen (PINP) and urinary deoxypyridinoline] were monitored over a period of 20 and 8 months, respectively. Following administration of denosumab, both patients demonstrated a rapid and pronounced biochemical response: Within 4–7 weeks, bone turnover markers fell to levels within the respective reference range, and one patient reported a reduction in pain. Treatment with denosumab was well tolerated. However, transient asymptomatic hypocalcaemia and/or hypophosphatemia associated with a transient two to threefold increase in serum PTH levels was observed in both patients. Dosing intervals for denosumab varied significantly between the two patients, depending on disease activity at baseline. Denosumab appears to be effective in reducing bone turnover in adult patients with active FD. However, caution should be exercised, and patients should be monitored carefully as significant fluctuations in biochemical and hormonal indices can occur.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

References

  1. Collins MTR, M. Bianco, P. (2008) Fibrous Dysplasia. In: Rosen C (ed) Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism, 7th edn. The American Society for Bone and Mineral Research, pp 423-427

  2. Yamamoto T, Ozono K, Kasayama S, Yoh K, Hiroshima K, Takagi M, Matsumoto S, Michigami T, Yamaoka K, Kishimoto T, Okada S (1996) Increased IL-6 production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune–Albright Syndrome. J Clin Investig 98(1):30–35

    Article  CAS  PubMed  Google Scholar 

  3. Riminucci M, Kuznetsov SA, Cherman N, Corsi A, Bianco P, Robey PG (2003) Osteoclastogenesis in fibrous dysplasia of bone: in situ and in vitro analysis of IL-6 expression. Bone 33(3):434–442

    Article  CAS  PubMed  Google Scholar 

  4. Weinstein LS, Shenker A, Gejman P, Merino MJ, Friedman E, Spiegel AM (1991) Activating mutations of the stimulatory G protein in the McCune-Albright Syndrome. N Engl J Med 325:1688–1695

    Article  CAS  PubMed  Google Scholar 

  5. Albright F, Butler A, Hampton A, Smith P (1937) Syndrome characterized by osteitis fibrosa disseminata, areas of pigmentation and endocrine dysfunction, with precocious puberty in females. N Engl J Med 216(17):727–746

    Article  Google Scholar 

  6. Riminucci M, Collins MT, Fedarko N, Cherman N et al (2003) FGF-23 in fibrous dysplasia of bone and its relationship to renal phosphate wasting. J Clin Investig 112(5):683–692

    CAS  PubMed  Google Scholar 

  7. Chapurlat RD, Delmas PD, Liens D, Meunier PJ (1997) Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 12(10):1746–1752

    Article  CAS  PubMed  Google Scholar 

  8. Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ (2004) Treatment of fibrous dysplasia of bone with intravenous pamidronate: long-term effectiveness and evaluation of predictors of response to treatment. Bone 35(1):235–242

    Article  CAS  PubMed  Google Scholar 

  9. Parisi MS, Oliveri B, Mautalen CA (2003) Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia. Bone 33(4):582–588

    Article  CAS  PubMed  Google Scholar 

  10. Weinstein RS (1997) Long-term aminobisphosphonate treatment of fibrous dysplasia: spectacular increase in bone density. J Bone Miner Res 12(8):1314–1315

    Article  CAS  PubMed  Google Scholar 

  11. Kitagawa Y, Tamai K, Ito H (2004) Oral alendronate treatment for polyostotic fibrous dysplasia: a case report. J Orthop Sci 9(5):521–525

    PubMed  Google Scholar 

  12. Chapurlat RD (2006) Medical therapy in adults with fibrous dysplasia of bone. J Bone Miner Res 21(Suppl 2):P114–P119

    Article  CAS  PubMed  Google Scholar 

  13. Plotkin H (2003) Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 88(10):4569–4575

    Article  CAS  PubMed  Google Scholar 

  14. Boyce AM, Chong WH, Yao J, Gafni RI, Kelly MH, Chamberlain CE, Bassim C, Cherman N, Ellsworth M, Kasa-Vubu JZ, Farley FA, Molinolo AA, Bhattacharyya N, Collins MT (2012) Denosumab treatment for fibrous dysplasia. J Bone Miner Res 27(7):1462–1470

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  15. Papapoulous SE (2008) Bisphosphonates for postmenopausal osteoporosis. In: Rosen C (ed) Primer on the metabolic bone diseases and disorders of mineral metabolism, 7th edn. The American Society for Bone and Mineral Research, pp 237-241

  16. Weinstein RS, Roberson PK, Stavros CM (2009) Giant osteoclast formation and long-term oral bisphosphonate therapy. N Engl J Med 360:53–62

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  17. Cummings SR, San Martin J, McClung MR, Siris ES, Eastell R, Reid IR, Delmas P, Zoog HB, Austin M, Wang A, Kutilek S, Adami S, Zanchetta J, Libanati C, Libanati C, Siddhanti S, Christiansen C (2009) Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 361:756–765

    Article  CAS  PubMed  Google Scholar 

  18. Piersanti S, Remoli C, Saggio I, Funari A, Michienzi S, Sacchetti B, Robey PG, Riminucci M, Bianco P (2010) Transfer, analysis, and reversion of the fibrous dysplasia cellular phenotype in human skeletal progenitors. J Bone Miner Res 25(5):1103–1116

    CAS  PubMed  Google Scholar 

  19. Mansoori LS, Catel CP, Rothman MS (2010) Bisphosphonate treatment in polyostotic fibrous dysplasia of the cranium: case report and literature review. Endocr Pract 16(5):851–854

    Article  PubMed  Google Scholar 

  20. Dumitrescu CE, Collins MT (2008) McCune-Albright syndrome. Orphanet J Rare Dis 3:12

    Article  PubMed Central  PubMed  Google Scholar 

  21. Miller PD, Wagman RB, Peacock M, Lewiecki EM, Bolognese MA, Weinstein RL, Ding B, San Martin J, McClung MR (2011) Effect of denosumab on bone mineral density and biochemical markers of bone turnover: six-year results of a phase 2 clinical trial. J Clin Endocrinol Metab 96(2):394–402

    Article  CAS  PubMed  Google Scholar 

  22. Grasemann C, Schundeln MM, Hovel M, Schweiger B, Bergmann C, Herrmann R, Wieczorek D, Zabel B, Wieland R, Hauffa BP (2013) Effects of RANK-ligand antibody (Denosumab) treatment on bone turnover markers in a girl with juvenile Paget’s disease. J Clin Endocrinol Metab 98(8):3121–3126

    Article  CAS  PubMed  Google Scholar 

  23. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR (2007) Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 356(18):1809–1822

    Article  CAS  PubMed  Google Scholar 

  24. Talreja DB (2012) Severe hypocalcemia following a single injection of denosumab in a patient with renal impairment. J Drug Assess 1:30–33

    Article  Google Scholar 

Download references

Conflicts of interest

None.

Author information

Authors and Affiliations

  1. Department of Endocrinology and Metabolism, Concord Hospital, Level 6 Concord Hospital Medical Centre, Hospital Road, Concord, NSW, 2139, Australia

    K. Ganda & M. J. Seibel

  2. Bone Research Program, ANZAC Research Institute, The University of Sydney, Concord, NSW, 2139, Australia

    K. Ganda & M. J. Seibel

Authors
  1. K. Ganda
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. M. J. Seibel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to K. Ganda.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ganda, K., Seibel, M.J. Rapid biochemical response to denosumab in fibrous dysplasia of bone: report of two cases. Osteoporos Int 25, 777–782 (2014). https://doi.org/10.1007/s00198-013-2585-1

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00198-013-2585-1

Keywords

Search

Navigation